Page 30 - Deleware Medical Journal - September/October 2019
P. 30
A Retrospective Review of Glioblastoma Multiforme
in a Comprehensive Community Cancer Center
Trisha Pascall-Lopez, DO; Nicholas Petrelli, MD; Robert E. Hall McBride, CTR; Michael Guarino, MD
INTRODUCTION
Glioblastoma multiforme (GBM) of the brain is an uncommon yet almost universally fatal disease. The annual incidence of GBM is 3.21 per 100,000 in the United States.1 Despite modest advances in treatment
over the last two decades, prognosis and overall median survival remain poor. Currently, GBM has a median survival
of 15 months in those patients with good functional status who get triple modality therapy (debulking plus chemoradiation).2
In Delaware, most patients diagnosed
with GBM present to Christiana Care
Health System/Helen F. Graham Cancer Center for surgical resection. Surgical resection is an integral part of patient survival in addition to chemoradiation.
The aim of this retrospective study is to
(1) compare demographic characteristics
of GBM patients and outcomes treated in
a community-based cancer center with multi-institutional studies; (2) compare the median overall survival from GBM patients receiving optimal treatment (triple modality) with those who received less than optimal therapy at the Helen F. Graham Cancer Center during 2011 to 2015, and to median overall survival quoted in multi-institutional studies for the same treatments and (3) assess factors associated with median overall survival in a community-based cancer center.
METHODS
All adult patients with newly diagnosed
(WHO grade IV) from January 1, 2011, through December 31, 2015, were included. The Delaware Cancer Registry is a database that collects data pertaining to cancer in Delaware
to provide to health professionals, researchers, and organizations. Information provided for this study included patient demographics such with the hospital system, primary
site of tumor, ICD code for histology,
of last contact or death. Additional information obtained from cross- reference in electronic health records (EHR) included patient ethnicity, type of chemotherapy received, radiation
of the type of surgery performed,
date of recurrence, and the medical oncologist treating the patient if the patient received chemotherapy at
our institution. From 2011 to 2015,
of gross tumor resection plus or minus chemotherapy or radiation.
222
Del Med J | September/October 2019 | Vol. 91 | No. 5
